Tadalafil Tablet, Film Coated
Product Images NDC 0480-2310

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 0480-2310). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

New (Image 1)

Chemical structure diagram of the active ingredient tadalafil, showing its molecular framework with rings and bonds as part of its chemical composition.*

FDA Label Image

New (Image 10)

Tadalafil 5 mg film-coated tablets packaging label from Teva Pharmaceuticals, Inc. The label states tablets should not be split and entire dose should be taken. It contains storage instructions, warnings, and manufacturing information, and indicates a quantity of 30 tablets in the package.*

FDA Label Image

New (Image 11)

Tadalafil 20 mg tablets, USP, film-coated oral tablets by Teva Pharmaceuticals, Inc. The label indicates 30 tablets per package and includes dosage, storage instructions, and warnings. The package highlights that tablets should not be split and the entire dose must be taken as labeled.*

FDA Label Image

2 (Image 2)

This image contains four line graphs depicting blood pressure measurements over time. The graphs show the difference in standing systolic, standing diastolic, supine systolic, and supine diastolic blood pressure (BP) values comparing Tadalafil to placebo across a 96-hour period. The y-axes indicate BP difference in mmHg, and the x-axes show time in hours.*

FDA Label Image

3 (Image 3)

A two-panel line graph showing the effects of Tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg on systolic blood pressure over 24 hours. The top panel plots starting systolic blood pressure changes, and the bottom panel shows supine systolic blood pressure changes over time post-dose in hours.*

FDA Label Image

4 (Image 4)

A line graph showing systolic blood pressure (mmHg) changes over 12 hours after administration of tadalafil or placebo with doxazosin at 8:00 and 20:00. Four lines depict blood pressure trends for 20 mg tadalafil at 08:00 and 20:00 and placebo at both times, illustrating fluctuations in systolic BP post-dosing.*

FDA Label Image

5 (Image 5)

A pharmacokinetic line graph depicting plasma tadalafil concentration (µg/L) over time (hours). It compares concentrations after a single 20 mg dose, a single 5 mg dose, and daily 5 mg dosing following 5 consecutive days of administration, with error bars indicating variability.*

FDA Label Image

6 (Image 6)

A line graph depicting change from baseline in IPSS Total Score over 12 weeks of treatment comparing Tadalafil 5 mg and placebo. The x-axis represents duration of treatment in weeks, and the y-axis represents the change in score. Tadalafil 5 mg shows a greater decrease in IPSS score compared to placebo, with statistical significance noted.*

FDA Label Image

7 (Image 7)

A line graph depicting the change from baseline in IPSS total score over a 12-week treatment duration, comparing Tadalafil 5 mg with placebo. The y-axis shows change from baseline, and the x-axis shows treatment duration in weeks. The graph includes statistical significance markers (p<0.01) at weeks 4 and 12.*

FDA Label Image

7 (Image 8)

A line graph displaying least-squares mean change from baseline over 26 weeks of therapy, comparing Tadalafil/Finasteride versus Placebo/Finasteride. The x-axis shows weeks of therapy (0, 4, 12, 26), and the y-axis represents change from baseline. Data points include statistical markers indicating significance (p<0.001, p<0.05).*

FDA Label Image

9 (Image 9)

A line graph showing change from baseline in IPSS total score over 12 weeks, comparing Tadalafil 5 mg and placebo. The x-axis represents treatment duration in weeks (0 to 12), and the y-axis shows change from baseline in score, decreasing over time. Tadalafil 5 mg shows greater reduction in score than placebo, with statistical significance marked at 12 weeks (p<0.01).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.